ANI Pharmaceuticals ANIP shares rallied 10.6% in the last trading session to close at $84.35. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.1% loss over the past four weeks.
This surge in share price is attributable to the encouraging financial guidance announced by the company for full year 2026, which surpassed Wall Street expectations. ANI Pharmaceuticals estimates recording total net revenues of $1.055 billion to $1.115 billion, with about 60% of this revenue coming from its rare disease segment. The Zacks Consensus Estimate for the metric stood at $937.71 million.
This drugmaker is expected to post quarterly earnings of $2.02 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $233.91 million, up 22.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For ANI, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ANIP going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
ANI belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Arcutis Biotherapeutics, Inc. ARQT, closed the last trading session 5.1% lower at $26.78. Over the past month, ARQT has returned -2.8%.
For Arcutis Biotherapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.02. This represents a change of +122.2% from what the company reported a year ago. Arcutis Biotherapeutics currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Arcutis Biotherapeutics, Inc. (ARQT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
